ADGI:NSD-Adagio Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.37

Change

-0.13 (-3.71)%

Market Cap

USD 0.38B

Volume

0.68M

Avg Analyst Target

USD 4.67 (+38.48%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

ADGI Stock Forecast & Price:
Based on the Adagio Therapeutics Inc stock forecasts from 2 analysts, the average analyst target price for Adagio Therapeutics Inc is USD 4.67 over the next 12 months. Adagio Therapeutics Inc’s average analyst rating is Sell. Stock Target Advisor’s own stock analysis of Adagio Therapeutics Inc is Slightly Bullish , which is based on 2 positive signals and 1 negative signals. At the last closing, Adagio Therapeutics Inc’s stock price was USD 3.37. Adagio Therapeutics Inc’s stock price has changed by +3.69% over the past week, +6.65% over the past month and 0% over the last year.

About Adagio Therapeutics Inc (ADGI:NSD)

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutra ...Read More

Company Website : https://adagiotx.com

Address : 303 Wyman Street, Waltham, MA, United States, 02451

Employees : 101

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 59.50

Short Ratio : 4.33

52 Week Low : 2.41

Shorted Shares : 4,382,418

200 Day Moving Average : 13.73

Shorted Shares Previous Month : 4,688,673

50 Day Moving Average : 2.97

Shares Held By Insiders : 53.50%

Short Percentage : 23.97%

Shares Held by Institutions : 66.88%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+1.66 (+0.58%)

 USD73.48B 29.71 20.69
REGN Regeneron Pharmaceuticals Inc

+1.16 (+0.19%)

 USD65.40B 8.39 6.44
MRNA Moderna Inc

+5.59 (+3.73%)

 USD59.64B 4.20 3.05
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

+3.53 (+2.24%)

 USD38.28B 2.86 1.54
SGEN Seagen Inc

-3.34 (-1.85%)

 USD33.15B 55.02 -51.02
RPRX Royalty Pharma Plc

+0.41 (+0.96%)

 USD28.81B 29.89 16.23
GMAB Genmab AS

+0.51 (+1.53%)

 USD21.88B 64.29 5.76
ARGX argenx NV ADR

+4.98 (+1.32%)

 USD20.88B N/A -31.64
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing ADGI

Symbol Name Weight Mer Price(Change) Market Cap
GERM ETFMG Treatments Testing .. 0.00 % 0.68 %

+0.94 (+3.91%)

 N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -53.58% 35% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.58% 35% F 23% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.38B 69% D+ 54% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.84 75% C 81% B-
Price / Cash Flow Ratio -2.08 42% F 62% D-
EV/EBITDA 0.52 23% F 52% F
Management Effectiveness  
Return on Equity -68.48% 42% F 18% F
Return on Invested Capital -77.91% 30% F 13% F
Return on Assets -37.19% 27% F 9% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 4.33 55% F 40% F
Short Percent 23.97% 4% F 7% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.